STOCK TITAN

Pluri Inc. - $PLUR STOCK NEWS

Welcome to our dedicated page for Pluri news (Ticker: $PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pluri's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pluri's position in the market.

Rhea-AI Summary
Pluri Inc. announces significant advancements in its various divisions including PluriAgtech, PluriCDMO, PluriHealth, and PluriFood, with notable collaborations and partnerships. The company secured a $4.2 million contract with the U.S. NIH and formed a new partnership with Bar-Ilan University. A landmark collaboration with Tnuva Group is driving technology forward, attracting global interest.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
none
-
Rhea-AI Summary
Pluri Inc. announced the launch of its cell-based coffee business activity, aiming to revolutionize the traditional coffee industry by leveraging its proprietary 3D technology platform. The company's cell-based coffee is designed to address the growing global demand for sustainable, high-quality coffee at mass scale production. Pluri's innovative product is estimated to reduce water usage by 98% and growing areas by 95%, thus preventing deforestation. The company aims to spin out its cell-based coffee as a new subsidiary focused on developing innovative products, technologies, and intellectual property for the coffee industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.79%
Tags
none
-
Rhea-AI Summary
Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) has launched a new revenue-generating Contract Development and Manufacturing Organization (CDMO) division, PluriCDMO™. The division aims to help innovative companies develop and manufacture life-changing therapies within the rapidly growing $5.2 billion cell and gene therapy sector. PluriCDMO™ will offer manufacturing support from the preclinical and development stages to late stage clinical and commercial production, including fill and finish and logistics. The division is headed by Andy Lewin, an experienced CDMO executive. PluriCDMO™ will utilize a state-of-the-art Good Manufacturing Practice (GMP) facility and a proprietary bioreactor system enabling 3D cell expansion and supporting the manufacture of stem cells, Induced Pluripotent Stem Cells, Exosomes, and Immuno therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
none
Rhea-AI Summary
Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) has signed an agreement with Bar-Ilan University's BIRAD Research & Development Company Ltd. to develop and commercialize PLX cells as a treatment for cocaine addiction. The agreement allows BIRAD to receive the right to further develop and commercialize the product, with Pluri entitled to 20% revenue sharing from future sales of the product for anti-addiction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.64%
Tags
none
-
Rhea-AI Summary
Pluri Inc. announces the publication of a successful Phase I study on PLX-R18, a placental-derived cell therapy for hematopoietic cell transplantation (HCT). The study showed increased blood cell counts for up to 12 months and a reduction in the need for blood transfusions. PLX-R18 has been granted Orphan Drug Designation by the FDA. The results support the development of PLX-R18 for hematologic acute radiation syndrome (H-ARS).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
-
Rhea-AI Summary
Pluri Inc. appoints Lorne Abony to its Board of Directors. Abony is a successful entrepreneur with experience in building multi-billion-dollar global businesses. He will contribute to Pluri's strategic growth plans by utilizing its cell-expansion technology platform in various sectors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
Pluri Inc.

Nasdaq:PLUR

PLUR Rankings

PLUR Stock Data

32.93M
3.16M
24.62%
10.7%
0.25%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
HAIFA

About PLUR

pluristem therapeutics inc. (nasdaqcm: psti, tase: psti/pltr) is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3d) technology platform to develop cell therapies for conditions such as inflammation, ischemia, hematological disorders, or exposure to radiation. pluristem’s placental expanded (plx) cells are placenta-derived, mesenchymal-like adherent stromal cells that are designed to be administered to patients without the need for tissue or genetic matching. these cells release soluble biomolecules, such as cytokines, chemokines and growth factors, which act in a paracrine or endocrine manner to facilitate healing of damaged tissues by stimulating the body’s own regenerative mechanisms. the company’s proprietary, 3d expansion technology can be used to grow plx cells in mass quantities with batch-to-batch consistency at pluristem’s fda, ema and pmda-approved, state-of-the art manufacturing facility. pluristem’s first product candi